In a constant battle to find more efficient and effective ways to test oncology preclinical candidates, 3D in vitro culture methods for PDX-derived tumor cells have shown promise of in vivo-like growth characteristics, invasion, and responses to therapeutics. With these methods, we can perform high-throughput in vitro PDX screening that identifies active and selective molecules, and select favorable PDX tumor models for subsequent validation of candidates in vivo.

This webinar discusses optimal approaches to leveraging both of these technologies within a preclinical program.


  • Leo Price, PhD, CEO, Ocello
  • Julia Schüler, PhD, Head of In Vivo Operations, Charles River